ABL is a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of virus for vaccine candidates, gene and cancer therapies. ABL’s mission is to provide GMP viral vectors from early-stage to market, contributing to the success of their clients’ innovations.
ABL’s CDMO services offer a one-stop-shop and end-to-end CMC including bulk drug substance, fill/finish of drug products, process and assay development, as well as bioanalytical testing. ABL has a unique experience with a broad range of viral vectors including poxvirus, arenavirus, lentivirus and adeno associated virus (AAV).
ABL is a subsidiary of the Institut Mérieux Group and operates from various locations in Europe and the US.